Glucomannan is one of the few ingredients with a permitted claim on the GB Nutrition and Health Claims Register, specifically in the context of contributing to weight loss as part of an energy-restricted diet when taken at 3 g per day
10.1161/01.CIR.100.10.1134
The FDA approved Zepbound in December 2024 as the first medication to treat sleep apneaa significant breakthrough
qw, once weekly
Del Prato, S., et al., Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Specifically, in ischemic/high-ROS environments, BACH1 tends to be degraded and acts to suppress angiogenesis by inhibiting the Wnt/-catenin signaling pathway and recruiting HDAC1, among other mechanisms